Management of Premature Ventricular Complexes

Initial Risk Stratification

The American College of Cardiology and the American Heart Association recommend that patients with symptomatic PVCs in structurally normal hearts be treated with beta-blockers or nondihydropyridine calcium channel blockers as first-line therapy, with catheter ablation reserved for medication failure, intolerance, or patient preference 1, 2
A PVC burden of >20-24% of total heartbeats carries the highest risk of PVC-induced cardiomyopathy, though concern begins at >10-15% 3
Very frequent PVCs (>10,000-20,000 per day) can cause left ventricular dysfunction 4

The American College of Cardiology recommends that symptomatic patients with structurally normal hearts be treated with beta-blockers (metoprolol, carvedilol) or nondihydropyridine calcium channel blockers (verapamil, diltiazem) as first-line therapy 1, 2
The European Society of Cardiology recommends that patients with PVC-induced cardiomyopathy (reduced LVEF with high PVC burden) be treated with beta-blockers immediately while optimizing guideline-directed heart failure therapy 5, 3
Catheter ablation is indicated when medications are ineffective, not tolerated, or not the patient's preference, with success rates reaching 80% and low complication rates 1, 2

The European Heart Association recommends that patients with structural heart disease optimize heart failure medications per current guidelines first, and consider amiodarone or catheter ablation after first episode of sustained VT in ICD patients 5
The American College of Cardiology recommends that post-myocardial infarction patients avoid aggressive PVC suppression with Class IC agents (flecainide, encainide, moricizine) due to increased mortality risk, and instead use beta-blockers as the cornerstone of therapy 6, 1

The American College of Cardiology recommends that athletes with ≥2,000 PVCs/24h undergo further evaluation, including ambulatory Holter monitoring, echocardiogram, and exercise stress test, as 30% of these athletes may have underlying structural heart disease 7

The European Heart Journal suggests that catheter ablation can restore ventricular function when PVCs are successfully suppressed in patients with PVC-induced cardiomyopathy, characterized by unexplained LVEF dysfunction with PVC burden ≥10% 8

The European Heart Journal recommends considering amiodarone for symptomatic PVCs or non-sustained VT in heart failure patients, and catheter ablation can improve LVEF when PVCs contribute to dysfunction 8
The European Heart Journal suggests that ablation is indicated as adjunctive therapy for patients receiving multiple ICD shocks from sustained VT not manageable by reprogramming 9

The American College of Cardiology advises against using detraining as a diagnostic or therapeutic measure in athletes, as studies have not confirmed its prognostic value 7, 10

The American College of Cardiology and the American Heart Association recommend catheter ablation as first-line therapy for patients with high-burden PVCs (>15% of total beats) and symptoms, if antiarrhythmic medications are ineffective, not tolerated, or not the patient's preference 11, 12
The American College of Cardiology recommends proceeding directly to catheter ablation if medications fail, cause intolerable side effects, or the patient prefers ablation, with a Class I recommendation 11, 12
Catheter ablation is indicated as primary therapy when PVC burden ≥10% and left ventricular ejection fraction (LVEF) is reduced without other explanation, according to the European Society of Cardiology 13, 11, 12
The European Society of Cardiology suggests that ablation can restore ventricular function when PVCs are successfully suppressed, making it the treatment of choice in patients with PVC-induced cardiomyopathy 13

The American College of Cardiology recommends considering amiodarone if beta-blockers are insufficient for patients with PVC-induced cardiomyopathy, though ablation is preferred for definitive treatment 13
The American Heart Association recommends proceeding with catheter ablation when PVC burden >15% with declining ventricular function (suspected PVC-induced cardiomyopathy) and medications are ineffective, not tolerated, or not preferred 11, 12